Encompass Health CORP 8-K filings

Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.

NYSE
Encompass Health Corporation announced the issuance of $500 million in aggregate principal amount of 5.875% Senior Notes due 2034 to fund debt repayment and operational expenses.
NYSE
Encompass Health Corporation has priced a $500 million private offering of 5.875% senior notes due 2034 to refinance existing debt.
NYSE
Encompass Health Corporation's annual meeting saw strong shareholder approval for director elections, auditor ratification, and executive compensation.
NYSE
Encompass Health reported strong first-quarter 2026 growth and raised its full-year financial guidance.
NYSE
Encompass Health reported robust fourth-quarter and full-year 2025 results, driven by capacity expansion and strong operational performance, alongside optimistic 2026 guidance.
NYSE
Encompass Health Corporation announced the election of Cain A. Hayes, former CEO of Point32Health, to its Board of Directors, bringing significant healthcare payor expertise.
NYSE
Encompass Health Corporation reiterates its full-year 2025 financial guidance for net operating revenue, Adjusted EBITDA, and Adjusted earnings per share ahead of investor meetings.
NYSE
Encompass Health Corporation reported robust third-quarter 2025 results, exceeding expectations and prompting an increase in its full-year financial guidance.
NYSE
Patricia Maryland has retired from Encompass Health Corporation's board of directors effective September 17, 2025, citing health reasons.
NYSE
Encompass Health Corporation reiterates its full-year 2025 financial guidance ahead of upcoming investor and analyst meetings.
NYSE
Encompass Health Corporation announced robust second-quarter 2025 financial results, exceeding expectations and raising its full-year guidance across key metrics.
NYSE
Encompass Health Corporation has published its Investor Reference Book, detailing a strong business outlook, aggressive growth strategy, and solid financial health, reinforcing its leadership in the inpatient rehabilitation sector.
NYSE
Encompass Health Corporation reiterated its full-year 2025 financial guidance for net operating revenue, Adjusted EBITDA, and Adjusted earnings per share ahead of scheduled investor and analyst meetings in June.
NYSE
Encompass Health Corporation's stockholders approved the 2025 Omnibus Performance Incentive Plan at the company's annual meeting on May 1, 2025.
NYSE
Encompass Health announced strong first-quarter results, increased its full-year guidance, and appointed Patrick Tuer as its new Chief Operating Officer.
NYSE
Encompass Health Corporation's Board of Directors has approved compensation increases for its top executives, including the CEO, effective for 2025.
NYSE
Encompass Health reports a robust fourth quarter in 2024, driven by discharge growth and issues a promising outlook for 2025.
NYSE
Encompass Health reported strong third-quarter results, driven by significant discharge growth, leading to an increase in full-year guidance.
NYSE
Encompass Health reported a strong second quarter in 2024, with revenue and Adjusted EBITDA growth, leading to an increase in full-year guidance.
NYSE
Encompass Health released an Investor Reference Book detailing its business overview, growth strategy, and operational initiatives within the inpatient rehabilitation sector.
NYSE
Encompass Health reiterates its full-year 2024 financial guidance during the Leerink Partners Healthcare Crossroads Conference.
NYSE
Encompass Health Corporation held its 2024 annual meeting, electing all nominated directors, ratifying its accounting firm, and approving executive compensation, while a diversity report proposal failed to pass.
NYSE
Encompass Health reported a 13.4% increase in revenue and a 19.2% increase in Adjusted EBITDA for the first quarter of 2024, leading to an increase in full-year guidance.
NYSE
Encompass Health reiterates its full-year 2024 financial guidance during the Barclays Global Healthcare Conference, maintaining its previously reported revenue, EBITDA, and earnings per share expectations.
NYSE
Encompass Health's Board of Directors has approved increases in the target long-term incentive for the CEO and the base salary for the General Counsel.
NYSE
Encompass Health reports a cybersecurity incident at Change Healthcare, its payment claims processor, which has temporarily disrupted payment submissions but has not otherwise impacted operations.
NYSE
Encompass Health reported a strong finish to 2023 with a 9.6% increase in net operating revenue and Adjusted EBITDA for the fourth quarter, driven by strong discharge growth.